Genomic Cancer Medicine Is the Future Now?

By Daniela Matei1; Susan Gubar2

1. Department of Obstetrics and Gynecology, Northwestern University, Evanston, IL 2. Department of English, Indiana University, Bloomington, IN

Published on

Bio

Daniela Matei Daniela Matei, M.D. is a Diana Princess of Wales Professor in Cancer Research in the Department of Obstetrics and Gynecology at Northwestern University Feinberg School of Medicine and the co-Leader of the Translational Research is Solid Tumors Program in the Robert H. Lurie Comprehensive Cancer Center. She is a physician scientist well-known in the field of ovarian cancer. Dr. Matei earned her M.D. from the University of Medicine and Pharmacy “Carol Davila” in Bucharest, Romania and completed post graduate training at SUNY at Stony Brook and at UCLA. She was a Professor at Indiana University in the Division of Hematology Oncology and served as the Co-leader of the Experimental and Developmental Therapeutics Program of the Indiana University Simon Cancer Center since 2007. Dr. Matei’s research has been continuously funded by the National Cancer Institute, the US Department of Veteran Affairs, the Department of Defense, the American Cancer Society, the V Foundation, and the Ovarian Cancer Research Fund.

Dr. Matei’s laboratory studies mechanisms of ovarian cancer metastasis and novel therapeutics for ovarian cancer. The general theme is translation between bench and clinic; with laboratory research forming the foundation of clinical experiments. She is also engaged in clinical research and serves as the principal investigator and/or co-investigator on many clinical trials testing novel therapies for ovarian cancer, including several cooperative group and National Cancer Institute–sponsored trials for gynecologic cancer.

Susan Gubar A Distinguished Professor Emeritus at Indiana University, Susan Gubar is the co-author and co-editor of “The Madwoman in the Attic” and the “Norton Anthology of Literature by Women.” She has produced a range of other books on representations of gender, sexuality, race, and ethnicity.

Since Susan Gubar was diagnosed with late-stage ovarian cancer in 2008, she has attempted to clarify the perspective of patients: in her “Memoir of a Debulked Woman,” in the handbook “Reading and Writing Cancer,” and in her New York Times column “Living with Cancer.”

Susan Gubar has been elected a member of the American Philosophical Society and the American Academy of Arts and Sciences. In 2013 with her collaborator Sandra M. Gilbert, she received the National Book Critic Circle’s Lifetime Achievement Award. In 2014, the National Coalition for Cancer Survivorship awarded her the Natalie Davis Spingarn Writers Award.

Sponsored by

Cite this work

Researchers should cite this work as follows:

  • Daniela Matei, Susan Gubar (2020), "Genomic Cancer Medicine Is the Future Now?," https://nanohub.org/resources/33473.

    BibTex | EndNote

Time

Location

Honors Hall, Purdue University West Lafayette, IN

Tags

Genomic Cancer Medicine Is the Future Now?
  • Genomic Cancer Medicine Is the Future Now? 1. Genomic Cancer Medicine Is the… 0
    00:00/00:00
  • The History…. 2. The History…. 409.0423757090424
    00:00/00:00
  • The History… 3. The History… 462.595929262596
    00:00/00:00
  • The history… 4. The history… 497.56423089756424
    00:00/00:00
  • Modern Surgery 5. Modern Surgery 545.84584584584582
    00:00/00:00
  • Sequencing of the human genome 6. Sequencing of the human genome 547.38071404738071
    00:00/00:00
  • Genomic Medicine in Cancer 7. Genomic Medicine in Cancer 565.13179846513185
    00:00/00:00
  • Mutations in two patients 8. Mutations in two patients 629.06239572906247
    00:00/00:00
  • From standard therapy 9. From standard therapy 678.57857857857857
    00:00/00:00
  • ….to targeted therapy 10. ….to targeted therapy 734.50116783450119
    00:00/00:00
  • 11. "Imatinib (Gleevec) Changed Ev… 919.386052719386
    00:00/00:00
  • Targeted Cancer Therapy 12. Targeted Cancer Therapy 922.42242242242241
    00:00/00:00
  • Targeted Cancer Therapy 13. Targeted Cancer Therapy 940.87420754087429
    00:00/00:00
  • PARP inhibition in BRCA deficient cells 14. PARP inhibition in BRCA defici… 985.01835168501839
    00:00/00:00
  • PARP Inhibition in BRCA Mutated Ovarian Cancer 15. PARP Inhibition in BRCA Mutate… 1149.6162829496163
    00:00/00:00
  • PARP Inhibition in BRCA Mutated Ovarian Cancer 16. PARP Inhibition in BRCA Mutate… 1150.950950950951
    00:00/00:00
  • Exceptional Responders Long Survivors 17. Exceptional Responders Long Su… 1203.0363697030364
    00:00/00:00
  • Survivorship 18. Survivorship 1286.4864864864865
    00:00/00:00
  • Cancer Prevention and Detection 19. Cancer Prevention and Detectio… 1338.7721054387721
    00:00/00:00
  • Missing Bullet Holes Theory—Abraham Wald 20. Missing Bullet Holes Theory—… 1437.203870537204
    00:00/00:00
  • The way forward: A dialogue 21. The way forward: A dialogue 1592.0587253920587
    00:00/00:00